Chengdu Lier Pharmaceuticals Co., Ltd.

To evaluate the relative bioavailability of the test preparation and the reference preparation in healthy subjects in the fasting state, the degree of human variation, and whether the PK blood sample collection time is reasonable and safe.

Main purpose To observe the in vivo pharmacokinetic process of propranolol hydrochloride drops (XZ21026) in healthy Chinese subjects after a single oral administration, estimate the corresponding pharmacokinetic parameters, and use the propranolol hydrochloride oral solution (trade name: HEMANGEOL) licensed by PIERRE FABRE DERMATOLOGIE and marketed in the United States as the original dosage form reference preparation ("Catalogue of Reference Preparations for Chemical Generic Drugs (22nd Batch)") to conduct human bioequivalence evaluation. Secondary purpose 1. Observe the safety of propranolol hydrochloride drops (XZ21026) in healthy humans; 2. Evaluate and compare the palatability of propranolol hydrochloride drops (XZ21026) and propranolol hydrochloride oral solution in subjects.

To evaluate the bioequivalence and safety of single-dose cetirizine hydrochloride tablets and reference drug Zyrtec® in healthy Chinese adult subjects after fasting and postprandial administration.